Our busy Media and PR Team provide journalists with the most
up-to-date and precise information on all aspects of prostate
cancer, as quickly as possible. We deliver expert responses to the
latest developments in prostate cancer research, as well as facts,
figures and spokespeople to guide you through the issues
surrounding the disease.
We also have access to around 150 people across the UK who have
been affected by prostate cancer, and are willing to share their
experiences with the media - our Media Talkers scheme.
In the Media Centre, you will find all our latest news releases
and comments, as well as the resources you need to shape an
article, including facts, statistics and profiles of our spokespeople. If you do need
any further information, you can also find the contact
details for the Media and PR Team who will be able to
Please note that the Media Centre is a tool for journalists. For
all other enquiries, please contact the Prostate Cancer UK
switchboard on 020 8222 7622.
A new study has found that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.
Prostate Cancer UK has welcomed the Scottish Medicines Consortium’s (SMC) decision to recommend enzalutamide for use on the NHS in Scotland for men with incurable prostate cancer.
Research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool and partly funded by Cancer Research UK may take us a step closer to overcoming one of the biggest problems in prostate cancer treatment – telling slow-growing tumours from aggressive ones.
Deaths from prostate cancer have fallen by a fifth in the past 20 years, according to figures published by Cancer Research UK today (Friday 1 November 2013). These findings come on the first day of Movember, the month formerly known as November.